


OCTOBER 16, 2026  
*In-Person Symposium*

---

ASCC  
**CME MOC**  
ACCREDITED



# State of the Art in Benign Hematology, Hemostasis, and Thrombosis

2026 Update in Emerging  
Therapeutics



Memorial Sloan Kettering  
Cancer Center

# Overview

**This symposium provides a state-of-the-art update on benign hematology, hemostasis, and thrombosis, highlighting emerging therapies and contemporary approaches to patient management.**

Designed for hematologists, oncologists, advanced practice providers, and other healthcare professionals involved in the care of patients with benign hematologic disorders, the program will focus on the latest evidence and evolving clinical practices in the field.

## Key Topics

- **Advances in venous thromboembolism (VTE) management**, including pulmonary embolism, thrombosis in multiple myeloma, and novel anticoagulant strategies such as factor XI inhibitors.
- **Interventional and device-related thrombosis**, with updates on post-thrombotic syndrome and venous stenting.
- **Hematologic complications of cancer therapy**, including chemotherapy-induced cytopenias, the use of thrombopoietin receptor agonists, and immunotherapy-related complications such as hemophagocytic lymphohistiocytosis (HLH).
- **Emerging concepts in immune thrombocytopenia (ITP)**, featuring patient-centered perspectives and novel therapeutic approaches.

Through expert-led presentations and interactive discussions, participants will **explore challenging real-world management scenarios** in thrombosis, cancer-associated cytopenias, and immune-mediated platelet disorders.

The program will **emphasize multidisciplinary care, emerging therapeutics, and the integration of new evidence into clinical practice**. Ample time will be dedicated to audience questions and discussion with faculty, fostering practical learning and clinical application.

### Syllabus

Following the conclusion of the symposium, participants will receive **access to an online syllabus** containing PDF copies of the faculty presentations.

### Credit Information

This live activity has been approved to offer the following credit types:

- *AMA PRA Category 1 Credit(s)<sup>TM</sup>*
- ABIM Maintenance of Certification (MOC)
- ABPath Continuing Certification (CC)

Nursing continuing education credit is pending.



**Scan here** to register or visit:  
**[msk.org/BenignHemeSymposium](https://msk.org/BenignHemeSymposium)**

# Faculty

## Symposium Directors



**Jeffrey Zwicker, MD**

Chief, Hematology Service  
Memorial Sloan Kettering Cancer Center



**Avi Leader, MD**

Assistant Attending, Hematology Service  
Memorial Sloan Kettering Cancer Center

## Symposium Planning Committee



**Jodi Mones, MD**

Associate Program Director, Medical Oncology/Hematology  
Fellowship, Hematology Track;  
Associate Attending, Hematology Service  
Memorial Sloan Kettering Cancer Center



**Cy Wilkins, MD**

Assistant Attending, Hematology Service  
Memorial Sloan Kettering Cancer Center



**Varun Iyengar, MD**

Hematology-Oncology Fellow  
Memorial Sloan Kettering Cancer Center

## Guest Faculty



**James Bussel, MD**

Professor Emeritus of Pediatrics  
Weill Cornell Medical College



**Marc Carrier, MD, MSc, FRCPC**

Professor of Medicine  
University of Ottawa



**Adam Cuker, MD, MSTR**

Professor of Medicine and of Pathology & Laboratory Medicine;  
Chief, Section of Hematology  
Perelman School of Medicine, University of Pennsylvania



**Kristen Sanfilippo, MD, MPHS**

Associate Professor, Division of Hematology  
Washington University School of Medicine

**MSK Faculty**



**Laurent Frenzel, MD, PhD**

Visiting Investigator, Hematology Service  
Memorial Sloan Kettering Cancer Center



**Adie Friedman, MD**

Attending, Interventional Radiology Service  
Memorial Sloan Kettering Cancer Center



**Anna Marcelli, MD**

Associate Attending, Hematology Service  
Memorial Sloan Kettering Cancer Center



**Rekha Parameswaran, MD**

Attending Member, Hematology Service  
Memorial Sloan Kettering Cancer Center



# Join Us in New York City

This symposium will be offered exclusively in person at Memorial Sloan Kettering's Zuckerman Research Center in New York City. Please note that virtual participation will not be available.

**Mortimer B. Zuckerman Research Center**  
**417 East 68th Street**  
**New York, NY 10065**

For information about accommodations, parking, directions, and planning your visit, please visit [msk.org/cme](https://msk.org/cme).

# Agenda

Each lecture will conclude with an interactive Q&A session.

TIME	SESSIONS
7:30 a.m.	Breakfast and Check-in
7:55 a.m.	<b>Welcome and Introduction</b> Jeffrey Zwicker, MD

## **Venous Thrombosis : Something Old, Something New**

**MODERATOR:** Avi Leader, MD

8:00 a.m.	<b>Keynote Presentation</b>  <b>Pulmonary Embolism: Evidence, Controversies, and Emerging Strategies</b> Marc Carrier, MD, MSc, FRCPC
9:15 a.m.	<b>Multiple Myeloma and Venous Thromboembolism: Risk Prediction and Prevention</b> Laurent Frenzel, MD, PhD
9:45 a.m.	<b>FXIa Inhibitors for Venous Thrombosis</b> Jeffrey Zwicker, MD
10:15 a.m.	Break

## **Devices and Venous Thromboembolism: Where Do We Go From Here?**

**MODERATOR:** Anna Marcelli, MD

10:45 a.m.	<b>Interventions for Venous Thromboembolism</b> Adie Friedman
11:15 a.m.	<b>How to Manage Antithrombotic Therapy after Venous Stenting</b> Kristen Sanfilippo, MD, MPH
11:45 a.m.	Lunch Break

## Cancer Treatment–Related Cytopenia

MODERATOR: Cy Wilkins, MD

- 12:30 p.m. **Thrombopoietin Receptor Agonists in  
Chemotherapy-Induced Thrombocytopenia**  
Avi Leader, MD
- 1:00 p.m. **Unexpected Cytopenia After Chemotherapy:  
What Am I Missing?**  
Rekha Parameswaran, MD
- 1:30 p.m. **HLH Associated with Immunotherapy**  
Jodi Mones, MD

## Immune Thrombocytopenia:

### *The Future is Here*

MODERATOR: Varun Iyengar, MD

- 2:00 p.m. **The Burden of Living with Immune  
Thrombocytopenia**  
James Bussel, MD
- 2:30 p.m. **Emerging Therapeutics in Immune  
Thrombocytopenia**  
Adam Cuker, MD, MSTR
- 3:00 p.m. **Closing Remarks and Adjournment**  
Jeffrey Zwicker, MD

**“I have attended this course numerous times over the years and always come away having learned a great deal.”**

**“This course provided valuable new knowledge that has enhanced my ability to diagnose and treat my patients.”**

— PAST PARTICIPANTS

# Registration

## Registration Fees

Category	Early Rate	General Rate
Physicians (MDs, PhDs, DOs)	\$250	\$300
Advanced Practice Providers	\$200	\$250
Nurses and Other Healthcare Professionals	\$150	\$200
Residents and Fellows*	\$50	\$100
Industry Professional**	N/A	\$525

*\*Registration fees for Residents and Fellows are non-refundable.*

*\*\*An industry professional is defined as any individual, irrespective of their provider type (such as MDs, PhDs, APPs, RNs, etc.) that is employed by an ineligible company.*

**Early registration rates are available through September 4, 2026.**

Please note that early registration pricing is separate from other **discounted registration categories available to select participant groups**. For details and eligibility requirements, please review our policy on **Registration Discounts** on our website.



**Scan here** to register or visit:  
**[msk.org/BenignHemeSymposium](https://msk.org/BenignHemeSymposium)**



Memorial Sloan Kettering  
Cancer Center

**Continuing Medical Education**

**VISIT US ONLINE**

[msk.org/cme](https://msk.org/cme)

[Instagram/MSKcontinuingmedicaleducation](https://www.instagram.com/MSKcontinuingmedicaleducation)

[LinkedIn /MSK-CME](https://www.linkedin.com/company/MSK-CME)

[Facebook/MSKCME](https://www.facebook.com/MSKCME)

[X/MSKCME](https://twitter.com/MSKCME)